✦ LIBER ✦

Impact of High-Density Lipoprotein Cholesterol on Revascularization Procedures in Patients With Stable Ischemic Heart Disease: From the COURAGE trial*

✍ Scribed by Acharjee, Subroto; Boden, William; Hartigan, Pamela; Teo, Koon; Maron, David; Sedlis, Steven; Kostuk, William; Spertus, John; Dada, Marcin; Chaitman, Bernard; John Mancini, G.B.; Weintraub, William

Book ID: 122318465
Publisher: Elsevier
Year: 2014
Tongue: English
Weight: 172 KB
Volume: 8
Category: Article
ISSN: 1933-2874
DOI: 10.1016/j.jacl.2014.02.032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTER

HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL IS ASSOCIATED WITH RESIDUAL RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE DESPITE OPTIMAL LEVELS OF LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL: A POST HOC ANALYSIS FROM THE COURAGE TRIAL

✍ Acharjee, Subroto; Boden, William E.; Hartigan, Pamela M.; Teo, Koon K.; Maron, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Relation of Clinical Benefit of Raising

Relation of Clinical Benefit of Raising High-Density Lipoprotein Cholesterol to Serum Levels of Low-Density Lipoprotein Cholesterol in Patients With Coronary Heart Disease (from the Bezafibrate Infarction Prevention Trial)

✍ Ilan Goldenberg; Michal Benderly; Roy Sidi; Valentina Boyko; Alexander Tenenbaum 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 385 KB

Relation Between On-Treatment Increments

Relation Between On-Treatment Increments in Serum High-Density Lipoprotein Cholesterol Levels and Cardiac Mortality in Patients With Coronary Heart Disease (from the Bezafibrate Infarction Prevention Trial)

✍ Ilan Goldenberg; Uri Goldbourt; Valentina Boyko; Solomon Behar; Henrietta Reiche 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 206 KB

The role of niacin in raising high-densi

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Rationale and design of a secondary prev

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

✍ Uri Goldbourt; Solomon Behar; Henrietta Reicher-Reiss; Jacob Agmon; Elieser Kapl 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 888 KB

Impact of Optimal Medical Therapy With o

Impact of Optimal Medical Therapy With or Without Percutaneous Coronary Intervention on Long-Term Cardiovascular End Points in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)

✍ William E. Boden; Robert A. O'Rourke; Koon K. Teo; David J. Maron; Pamela M. Har 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 258 KB